Oh EJ - Search Results

1

An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration.

Yunn NO, Lee J, Lee HS, Oh EJ, Park M, Park S, Jin SY, Shin E, Lee JWY, Kim Y, Bae SS, Ryu SH. Yunn NO, et al. Among authors: oh ej. Exp Mol Med. 2022 Apr;54(4):531-541. doi: 10.1038/s12276-022-00760-w. Epub 2022 Apr 27. Exp Mol Med. 2022. PMID: 35478209 Free PMC article.

2

Signal transduction of hyaluronic acid-peptide conjugate for formyl peptide receptor like 1 receptor.

Oh EJ, Kim JW, Kong JH, Ryu SH, Hahn SK. Oh EJ, et al. Bioconjug Chem. 2008 Dec;19(12):2401-8. doi: 10.1021/bc800255y. Bioconjug Chem. 2008. PMID: 19007292

3

Theranostic systems assembled in situ on demand by host-guest chemistry.

Jung H, Park KM, Yang JA, Oh EJ, Lee DW, Park K, Ryu SH, Hahn SK, Kim K. Jung H, et al. Among authors: oh ej. Biomaterials. 2011 Oct;32(30):7687-94. doi: 10.1016/j.biomaterials.2011.06.060. Epub 2011 Jul 23. Biomaterials. 2011. PMID: 21788071

4

Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.

Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon JH. Cho Y, et al. Among authors: oh ej. PLoS One. 2016 Aug 5;11(8):e0160822. doi: 10.1371/journal.pone.0160822. eCollection 2016. PLoS One. 2016. PMID: 27494117 Free PMC article.

5

Long acting hyaluronate--exendin 4 conjugate for the treatment of type 2 diabetes.

Kong JH, Oh EJ, Chae SY, Lee KC, Hahn SK. Kong JH, et al. Among authors: oh ej. Biomaterials. 2010 May;31(14):4121-8. doi: 10.1016/j.biomaterials.2010.01.091. Epub 2010 Feb 10. Biomaterials. 2010. PMID: 20149450

6

A Novel Role of Serotonin Receptor 2B Agonist as an Anti-Melanogenesis Agent.

Oh EJ, Park JI, Lee JE, Myung CH, Kim SY, Chang SE, Hwang JS. Oh EJ, et al. Int J Mol Sci. 2016 Apr 12;17(4):546. doi: 10.3390/ijms17040546. Int J Mol Sci. 2016. PMID: 27077852 Free PMC article.

7

Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.

Oh EJ, Park K, Kim KS, Kim J, Yang JA, Kong JH, Lee MY, Hoffman AS, Hahn SK. Oh EJ, et al. J Control Release. 2010 Jan 4;141(1):2-12. doi: 10.1016/j.jconrel.2009.09.010. Epub 2009 Sep 13. J Control Release. 2010. PMID: 19758573 Review.

8

Synthesis, characterization, and preliminary assessment of anti-Flt1 peptide-hyaluronate conjugate for the treatment of corneal neovascularization.

Oh EJ, Park K, Choi JS, Joo CK, Hahn SK. Oh EJ, et al. Biomaterials. 2009 Oct;30(30):6026-34. doi: 10.1016/j.biomaterials.2009.07.024. Epub 2009 Jul 31. Biomaterials. 2009. PMID: 19647313

9

Anti-Flt1 peptide - hyaluronate conjugate for the treatment of retinal neovascularization and diabetic retinopathy.

Oh EJ, Choi JS, Kim H, Joo CK, Hahn SK. Oh EJ, et al. Biomaterials. 2011 Apr;32(11):3115-23. doi: 10.1016/j.biomaterials.2011.01.003. Epub 2011 Jan 28. Biomaterials. 2011. PMID: 21277020

10

Control of the molecular degradation of hyaluronic acid hydrogels for tissue augmentation.

Oh EJ, Kang SW, Kim BS, Jiang G, Cho IH, Hahn SK. Oh EJ, et al. J Biomed Mater Res A. 2008 Sep;86(3):685-93. doi: 10.1002/jbm.a.31681. J Biomed Mater Res A. 2008. PMID: 18022803

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

411 results

Search Page

Filters